Cleave Therapeutics

High-Level Overview

Cleave Therapeutics is a biopharmaceutical company developing small-molecule inhibitors targeting valosin-containing protein (VCP)/p97 to disrupt protein homeostasis and cellular stress pathways in cancer and neurodegenerative diseases.[1][2][3] Its lead candidate, CB-5339, is an oral, second-generation VCP/p97 inhibitor showing tolerability and clinical activity in Phase 1 trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), with ongoing compassionate use and planned trials in solid tumors.[1][2] The company serves oncology patients with unmet needs in solid tumors and hematologic malignancies, addressing cancer cell survival mechanisms dependent on VCP/p97.[1][2] Founded in 2011 and headquartered in San Francisco, it has raised $103M, with the last round in 2019, and transitioned assets like CB-5339 to CASI Pharmaceuticals while maintaining its pipeline focus.[1][4]

Origin Story

Cleave Therapeutics, formerly Cleave Biosciences, was founded in 2011 in San Francisco by biotech leaders targeting protein homeostasis for cancer therapies.[1][4] The idea emerged from research on p97 (VCP), a AAA ATPase critical to protein degradation and stress responses in cancer cells, building on collaborations with the National Cancer Institute (NCI) and academic institutions.[2][3] Early traction came with its first lead, CB-5083, an oral p97 inhibitor, followed by CB-5339, which advanced to Phase 1 trials in AML/MDS, demonstrating safety in 55 patients and anti-tumor activity, leading to asset transfer to CASI while Cleave pursues further VCP inhibitors.[1][2] This evolution shifted from broad protein homeostasis inhibitors to selective VCP/p97 targeting for oncology and neurodegeneration.[2][3]

Core Differentiators

• Novel Target Focus: Targets VCP/p97, an enzyme essential for cancer cell protein homeostasis, DNA damage repair, and stress pathways, with preclinical validation in AML, solid tumors, and hematologic cancers.[1][2][3]
• Advanced Pipeline: CB-5339 offers improved selectivity, exposure, and oral bioavailability over prior compounds like CB-5083, backed by Phase 1 data showing tolerability and activity; NCI-sponsored trials planned for solid tumors.[1][2]
• Collaborative Expertise: Partners with NCI and top academics to exploit VCP dependencies unique to cancer cells, enabling dual innate/adaptive anti-tumor responses.[2]
• Broad Therapeutic Potential: Extends beyond oncology to neurodegenerative diseases by modulating cellular stress, positioning it in high-unmet-need areas.[2][3]

Role in the Broader Tech Landscape

Cleave rides the protein degradation and targeted protein homeostasis trend in biotech, where inhibiting undruggable targets like VCP/p97 exploits cancer vulnerabilities amid rising resistance to immunotherapies and chemotherapies.[1][2] Timing aligns with surging interest in cellular stress pathways, fueled by NCI's long-term VCP research and post-2020 advances in degraders like PROTACs, amplifying demand for AML/MDS therapies amid an aging population and limited options.[1][2] Market forces favor it through partnerships accelerating trials and asset deals like CB-5339 to CASI, influencing the ecosystem by validating VCP as a platform for next-gen oncology tools and neurodegeneration.[1][3]

Quick Take & Future Outlook

Cleave's pivot to VCP/p97 inhibitors positions it for Phase 1 expansions in solid tumors via NCI and potential neurodegeneration readouts, with trends like AI-driven target discovery and combo therapies boosting momentum.[2] Expect licensing deals or further spinouts amid biotech M&A recovery, evolving its influence from niche player to VCP pioneer in precision oncology. This builds on its protein homeostasis foundation, promising cures where traditional therapies fail.[1][2]